Patent · US Active

PIM-3 kinase as a target for type 2 diabetes mellitus

US8580251B2 · kind B2 · utility

0Cited by

1References

3Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Marc Korn · Offenbach, DE
Guenter Mueller · Pocking, DE
Rudolf Schneider · Niedernhausen, DE
Georg Tschank · Frankfurt am Main, DE

Key dates

Filing date	Oct 19, 2009
Grant date	Nov 12, 2013
Priority date	—
Expiry date	Oct 19, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N9/1205
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.